- <![CDATA[First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCC]]><![CDATA[Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.]]>onclive · 2mo ago↗ source
- <![CDATA[Cumulative ADC Toxicities and Closing Reflections: Managing Edema, Fatigue, and Optimizing Long-Term Tolerability]]><![CDATA[This concluding segment addresses cumulative toxicities affecting long-term antibody-drug conjugate tolerability, with Hope Rugo, MD and Aaron Lisberg, MD discussing edema, fatigue, and st…onclive · 2mo ago↗ source
- Odyssey, on second try, snags $279M in an IPO<figure><div><img src="https://imgproxy.divecdn.com/szYDL8kkQd6XaSVgvjJPYl2j0snveijWs_0sZ-B522Y/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xNDYyODUzODA3LmpwZ…